LIQUIDIA CORPORATION Cost of Revenue
LIQUIDIA CORPORATION (LQDA) reported Cost of Revenue of $1.52 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2025-05-08
- LIQUIDIA CORPORATION cost of goods and services sold for the quarter ending 2025-03-31 was $1.52M, a 3.41% increase year-over-year.
- LIQUIDIA CORPORATION cost of goods and services sold for the quarter ending 2024-12-31 was $1.35M, a 36.35% increase year-over-year.
- LIQUIDIA CORPORATION cost of goods and services sold for the quarter ending 2024-09-30 was $1.56M, a 174.56% increase year-over-year.
- LIQUIDIA CORPORATION cost of goods and services sold for the quarter ending 2024-06-30 was $1.49M, a 122.50% increase year-over-year.
- LIQUIDIA CORPORATION cost of goods and services sold for fiscal 2022 was $2.86M, a 5.43% decline from fiscal 2021.
- LIQUIDIA CORPORATION cost of goods and services sold for fiscal 2021 was $3.02M, a 1171.71% increase from fiscal 2020.
- LIQUIDIA CORPORATION cost of goods and services sold for fiscal 2020 was $237.71K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | $1.52M 10-Q · filed 2025-05-08 | $2.87M derived: sum of 2 quarters · filed 2025-05-08 | $4.44M derived: sum of 3 quarters · filed 2025-05-08 | $5.93M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2024-12-31 | $1.35M derived: 8-K 12 month − 10-Q 9 month · filed 2025-05-08 | $2.92M derived: sum of 2 quarters · filed 2025-05-08 | $4.41M derived: sum of 3 quarters · filed 2025-05-08 | $5.88M 8-K · filed 2025-05-08 | ||||
| 2024-09-30 | $1.56M 10-Q · filed 2024-11-13 | $3.06M derived: sum of 2 quarters · filed 2024-11-13 | $4.53M 10-Q · filed 2024-11-13 | $5.52M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2024-06-30 | $1.49M 10-Q · filed 2024-08-07 | $2.96M 10-Q · filed 2024-08-07 | $3.95M derived: sum of 3 quarters · filed 2025-05-08 | $4.52M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2024-03-31 | $1.47M 10-Q · filed 2025-05-08 | $2.46M derived: sum of 2 quarters · filed 2025-05-08 | $3.03M derived: sum of 3 quarters · filed 2025-05-08 | $3.70M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $993.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-05-08 | $1.56M derived: sum of 2 quarters · filed 2025-05-08 | $2.23M derived: sum of 3 quarters · filed 2025-05-08 | $2.89M 8-K · filed 2025-05-08 | ||||
| 2023-09-30 | $570.00K 10-Q · filed 2024-11-13 | $1.24M derived: sum of 2 quarters · filed 2024-11-13 | $1.90M 10-Q · filed 2024-11-13 | $2.59M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $671.00K 10-Q · filed 2024-08-07 | $1.32M 10-Q · filed 2024-08-07 | $2.02M derived: sum of 3 quarters · filed 2024-08-07 | $2.76M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $654.00K 10-Q · filed 2024-05-13 | $1.35M derived: sum of 2 quarters · filed 2024-05-13 | $2.09M derived: sum of 3 quarters · filed 2024-05-13 | $2.82M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.43M derived: sum of 2 quarters · filed 2024-03-13 | $2.17M derived: sum of 3 quarters · filed 2024-03-13 | $2.86M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $740.00K 10-Q · filed 2023-11-07 | $1.47M derived: sum of 2 quarters · filed 2023-11-07 | $2.17M 10-Q · filed 2023-11-07 | $2.89M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $731.00K 10-Q · filed 2023-08-10 | $1.43M 10-Q · filed 2023-08-10 | $2.15M derived: sum of 3 quarters · filed 2023-08-10 | $3.04M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $694.00K 10-Q · filed 2023-05-08 | $1.42M derived: sum of 2 quarters · filed 2023-05-08 | $2.31M derived: sum of 3 quarters · filed 2023-05-08 | $3.02M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | $726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.62M derived: sum of 2 quarters · filed 2023-03-20 | $2.33M derived: sum of 3 quarters · filed 2023-03-20 | $3.02M 10-K · filed 2023-03-20 | $3.02M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $890.00K 10-Q · filed 2022-11-08 | $889.51K 10-Q · filed 2021-11-03 | $1.60M derived: sum of 2 quarters · filed 2022-11-08 | $2.30M 10-Q · filed 2022-11-08 | $2.30M 10-Q · filed 2021-11-03 | $2.54M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $714.00K 10-Q · filed 2022-08-11 | $713.74K 10-Q · filed 2021-08-10 | $1.41M 10-Q · filed 2022-08-11 | $1.41M 10-Q · filed 2021-08-10 | $1.65M derived: sum of 3 quarters · filed 2022-08-11 | $1.65M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $694.00K 10-Q · filed 2022-05-12 | $693.74K 10-Q · filed 2021-05-13 | $931.71K derived: sum of 2 quarters · filed 2022-05-12 | $931.71K derived: sum of 3 quarters · filed 2022-05-12 | $931.71K derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $237.71K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $237.71K derived: sum of 2 quarters · filed 2022-03-17 | $237.71K derived: sum of 3 quarters · filed 2022-03-17 | $237.71K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |